Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer

Pancreatology

Volumn 1, Issue 4, 2001, Pages 291-299

  Ding, Xian Zhong ^a   Tong, Wei Gang ^a   Adrian, Thomas E ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma, pancreatic; Cyclooxygenases; Lipoxygenases

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOXYGENASE; PROSTAGLANDIN SYNTHASE;

ANIMAL; DRUG EFFECT; ENZYMOLOGY; HUMAN; PANCREAS TUMOR; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LIPOXYGENASE; PANCREATIC NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0035554401     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000055827     Document Type: Review

References (63)

1. Blackstock AW, Cox AD, Tepper JE: Treatment of pancreatic cancer: Limitations, future possibilities. Oncology 1996;10:308-323.
2. Silverberg E, Boring CC, Squires TS: Cancer statistics, 1990. J Am Cancer Soc 1990;40:9-26.
3. Hunstad DA, Norton JA: Management of pancreatic cancer. Surg Oncol 1995;4:61-74.
4. Serafini FM, Rosemurgy AS: New directions in systemic therapy of pancreatic cancer. Cancer Control 2000;7:437-444.
5. King TC, Mangray S: Molecular pathobiology of pancreatic adenocarcinoma. Front Biosci 1998;3:1148-1160.
6. Sigal E: The molecular biology of mammalian arachidonic acid metabolism. Am J Physiol 1991;260:L13-L28.
7. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.
8. Funk CD: The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1996;1304:65-84.
9. Brash AR: Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999;274:23679-23682.
10. Conrad DJ: The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. Clin Rev Allergy Immunol 1999;17: 71-89.
11. Radmark OP: The molecular biology and regulation of 5-lipoxygenase. Am J Respir Crit Care Med 2000;161:S11-S15.
12. Peters-Golden M: Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med 1998;157:S227-S232.
13. Nie D, Tang K, Szekeres K, Li L, Honn KV: Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann NY Acad Sci 2000;905:165-176.
14. Tang DG, Honn KV: Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: Role of 12-lipoxygenase in regulating tumor cell survival. J Cell Physiol 1997;172:155-170.
15. Gao X, Porter AT, Honn KV: Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 1997; 407:41-53.
16. Chen YQ, Duniec ZM, Liu B, Hagmann W, Gao X, Shimoji K, Marnett LJ, Honson CR, Honn KV: Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 1994;54:1574-1579.
17. Tiano H, Lee C, Loftin CD, Langenbach R: Cyclooxygenase-deficient mice. Ann NY Acad Sci 1999;889:52-61.
18. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-235.
19. Moore BC, Simmons DL: COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Curr Med Chem 2000;7:1131-1144.
20. Baron JA, Sandler RS: Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000;51:511-523.
21. Prescott SM, Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-M78.
22. Tang DG, Tarrien M, Dobrzynski P, Honn KV: Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK). J Cell Physiol 1995;165:291-306.
23. Honn KV, Tang DG, Grossi IM, Renaud C, Duniec ZM, Johnson CR, Diglio CA: Enhanced endothelial cell retraction mediated by 12(S)-HETE: A proposed mechanism for the role of platelets in tumor cell metastasis. Exp Cell Res 1994;210:1-9.
24. Tang DG, Chen YQ, Honn KV: Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 1996;93:5241-5246.
25. Natarajan R, Nadler J: Role of lipoxygenases in breast cancer. Front Biosci 1998;3:E81-E88.
26. Natarajan R, Esworthy R, Bai W, Gu JL, Wilczynski S, Nadler J: Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J Clin Endocrinol Metab 1997;82:1790-1798.
27. Ghosh J, Myers CE: Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997;235:418-423.
28. Ghosh J, Myers CE: Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol 1999;469:577-582.
29. Myers CE, Ghosh J: Lipoxygenase inhibition in prostate cancer. Eur Urol 1999;35:395-398.
30. Ghosh J, Myers CE: Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998;95:13182-13187.
31. Schuller HM, Tithof PK, Williams M, Plummer H: The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 1999;59:4510-4515.
32. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806-813.
33. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
34. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-146.
35. Ding XZ, Tong WG, Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:2625-2631.
36. Molinoa MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-4362.
37. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, Imamura M: Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999;26:69-76.
38. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori S, Monden M: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-2024.
39. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-338.
40. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-87.
41. DuBois RN, Giardiello FM, Smalley WE: Non-steroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-791.
42. Okuno K, Jinnai H, Lee YS, Nakamura K, Hirohata T, Shigeoka H, Yasutomi M: A high level of prostaglandin E2 (PGE2) in the portal vein suppresses liver-associated immunity and promotes liver metastases. Surg Today 1995; 25:954-958.
43. Morecki S, Yacovlev E, Gelfand Y, Trembovler V, Shohami E, Slavin S: Induction of antitumor immunity by indomethacin. Cancer Immunol Immunother 2000;48:613-620.
44. Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27.
45. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-4744.
46. Tzanakakis GN, Agarwal KC, Veronikis DK, Vezeridis MP: Effects of antiplatelet agents or in combination on platelet aggregation and on liver metastases from a human pancreatic cancer in the nude mouse. J Surg Oncol 1991;48: 45-50.
47. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA, Harris JE: 5-Lipoxygenase inhibitors reduce PANC-1 survival: The mode of cell death and synergism of MK866 with gamma linolenic acid. Anticancer Res 1998;18:791-800.
48. Ding XZ, Iversen P, Cluck MW, Knezetic JA, Adrian TE: Lipocygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 1999;26:218-223.
49. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE: Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 1999;266:392-399.
50. Anderson KM, Alrefai WA, Bonomi P, Dudeja P, Ou D, Anderson C, Harris JE: Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip. Anticancer Res 1999;19:3873-3887.
51. Tong WG, Ding XZ, Adrian TE: Inhibition of human pancreatic cancer growth by lipoxygenase inhibitors in the athymic mouse xenograft model. Pancreas 2000;21:485.
52. Connolly JM, Rose DP: Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. Cancer Lett 1998;132: 107-112.
53. Datta K, Biswal SS, Kehrer JP: The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J 1999;340:371-375.
54. Timar J, Li L, Grignon D, Nie D, Honn KV, Hagmann W: Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 2000;87:37-43.
55. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ, Honn KV: Platelet-type 12-lipoxygenase regulates angiogenesis in human prostate carcinoma. Adv Exp Med Biol 1999; 469:623-630.
56. Szekeres CK, Trikha M, Nie D, Honn KV: Eicosanoid 12(S)-HETE activates phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2000;275:690-695.
57. Szekeres CK, Tang K, Trikha M, Honn KV: Eicosanoid activation of extracellular signal-regulated kinase 1/2 in human epidermoid carcinoma cells. J Biol Chem 2000;275:38831-38841.
58. Ding XZ, Tong WG, Adrian TE: The 5-lipoxygenase metabolite, 5-HETE stimulates pancreatic cancer cell proliferation via multiple signaling pathways. Pancreas 2000;21:439.
59. Ding XZ, Adrian TE: 12-Lipoxygenase activity stimulates pancreatic cancer cell proliferation through activation of ERK MAP kinase pathway. Proc Am Assoc Cancer Res 2000;41:20.
60. Werz O, Klemm J, Samuelsson B, Randmark O: 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci USA 2000;97:5261-5266.
61. Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJ, Doran J, Pemberton G, Young AM, Buckels J, Kerr DJ: A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol 2000;11:1165-1170.
62. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2-inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275:11397-11403.
63. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-6850.